Fludarabine, mitoxantrone, and dexamethasone: An effective new regimen for indolent lymphoma

Journal of Clinical Oncology

Volumn 14, Issue 4, 1996, Pages 1262-1268

  McLaughlin, P ^a   Hagemeister, F B ^a   Romaguera, J E ^a   Sarris, A H ^a   Pate, O ^a   Younes, A ^a   Swan, F ^a   Keating, M ^a   Cabanillas, F ^a  

^a UNIVERSITY OF TEXAS MD ANDERSON CANCER CENTER   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

COTRIMOXAZOLE; DEXAMETHASONE; FLUDARABINE; GRANULOCYTE COLONY STIMULATING FACTOR; MITOXANTRONE;

ADULT; AGED; ARTICLE; BLOOD TOXICITY; BONE MARROW SUPPRESSION; CANCER COMBINATION CHEMOTHERAPY; CANCER SURVIVAL; CLINICAL TRIAL; DRUG EFFICACY; FEMALE; GASTROINTESTINAL TOXICITY; HUMAN; INTRAVENOUS DRUG ADMINISTRATION; LACTATE DEHYDROGENASE BLOOD LEVEL; LUNG TOXICITY; LYMPHOMA; MAJOR CLINICAL STUDY; MALE; NEUROTOXICITY; OPPORTUNISTIC INFECTION; PHASE 2 CLINICAL TRIAL; PNEUMOCYSTOSIS; PRIORITY JOURNAL;

EID: 0029991369     PISSN: 0732183X     EISSN: None     Source Type: Journal    
DOI: 10.1200/JCO.1996.14.4.1262     Document Type: Article

References (37)

1. McLaughlin P, Cabanillas F, Newland AC: Controversies in therapy for the low grade lymphomas, in Newland A, Burnett A, Keating A, et al (eds): Haematological Oncology. New York, NY, Cambridge University, 1991, pp 173-193
2. Redman JR, Cabanillas F, Velasquez WS, et al: Phase II trial of fludarabine phosphate in lymphomas: An effective new agent in low-grade lymphoma. J Clin Oncol 10:790-794, 1992
3. Höchster HS, Kim K, Green MD, et al: Activity of fludarabine in previously treated non-Hodgkin's low-grade lymphoma: Results of an Eastern Cooperative Oncology Group study. J Clin Oncol 10:28-32, 1992
4. Leiby JM, Snider KM, Kraut EH, et al: Phase II trial of 9-β-D-arabinofuranosyl-2-fluoroadenine-5′-monophosphate in non-Hodgkin's lymphoma: Prospective comparison of response with deoxycytidine kinase activity. Cancer Res 47:2719-2722, 1987
5. Gams RA, Bryan S, Dukart G, et al: Mitoxantrone in malignant lymphoma. Invest New Drugs 3:219-222, 1985
6. Coltman CA, McDaniel TM, Balcerzak SP, et al: Mitoxantrone hydrochloride (NSC-310739) in lymphoma. A Southwest Oncology Group study. Invest New Drugs 1:65-70, 1983
7. Silver RT, Case DC, Wheeler RH, et al: Multicenter clinical trial of mitoxantrone in non-Hodgkin's lymphoma and Hodgkin's disease. J Clin Oncol 9:754-761, 1991
8. McLaughlin P, Hagemeister FB, Swan F, et al: Phase I study of the combination of fludarabine, mitoxantrone, and dexamethasone in low-grade lymphoma. J Clin Oncol 12:575-579, 1994
9. Gribben JG: Attainment of molecular remission: A worthwhile goal? J Clin Oncol 12:1532-1534, 1994
10. Dixon DO, McLaughlin P, Hagemeister FB, et al: Reporting outcomes in Hodgkin's disease and lymphoma. J Clin Oncol 5:1670-1672, 1987
11. Shipp M, Harrington D, Anderson J, et al: A predictive model for aggressive non-Hodgkin's lymphoma. N Engl J Med 329:987-994, 1993
12. 2-microglobulin and lactate dehydrogenase levels. J Clin Oncol 7:1518-1527, 1989
13. Lopez-Guillermo A, Montserrat E, Bosch F, et al: Applicability of the International Index for aggressive lymphomas to patients with low-grade lymphoma. J Clin Oncol 12:1343-1348, 1994
14. Bastion Y, Coiffier B: Is the international prognostic index for aggressive lymphoma patients useful for follicular lymphoma patients? J Clin Oncol 12:1340-1342, 1994
15. Weisdorf D, Andersen J, Glick J, et al: Survival after relapse of low-grade non-Hodgkin's lymphoma: Implications for marrow transplantation. J Clin Oncol 10:942-947, 1992
16. Fisher RI, Dahlberg S, Nathwani BN, et al: A clinical analysis of two indolent lymphoma entities: mantle cell lymphoma and marginal zone lymphoma (including the mucosa-associated lymphoid tissue and monocytoid B-cell subcategories): A Southwest Oncology Group study. Blood 85:1075-1082, 1995
17. McLaughlin P, Hagemeister FB, Swan F, et al: Intensive conventional-dose chemotherapy for stage IV low-grade lymphoma: High remission rates and reversion to negative of peripheral blood bcl-2 rearrangement. Ann Oncol 5:S73-77, 1994 (suppl 2)
18. Cheson B: New antimetabolites in the treatment of human malignancies. Semin Oncol 19:695-706, 1992
19. Robertson L, Chubb S, Meyn R, et al: Induction of apoptotic cell death in chronic lymphocytic leukemia by 2-chloro-2′-deoxy-adenosine and 9-β-D-arabinosyl-2-fluoroadenine. Blood 81:143-150, 1993
20. Hockenbery D, Nunez G, Milliman C, et al: Bcl-2 is an inner mitochondrial membrane protein that blocks programmed cell death. Nature 348:334-338, 1990
21. Miyashita T, Reed JC: Bcl-2 oncoprotein blocks chemotherapy-induced apoptosis in a human leukemia cell line. Blood 81:151-157, 1993
22. Alexanian R, Dimopoulos MA, Delasalle K, et al: Primary dexamethasone treatment of multiple myeloma. Blood 80:887-890, 1992
23. Williams RS, Crowell RM, Fisher CM, et al: Clinical and radiologic remission in reticulum cell sarcoma of the brain. Arch Neurol 36:206-210, 1979
24. O'Brien S, Kantarjian H, Beran M, et al: Results of fludarabine and prednisone therapy in 264 patients with chronic lymphocytic leukemia with multivariate analysis-derived prognostic model for response to treatment. Blood 82:1695-1700, 1993
25. Velasquez WS, McLaughlin P, Tucker S, et al: ESHAP - An effective chemotherapy regimen in refractory and relapsing lymphoma: A 4-year follow-up study. J Clin Oncol 12:1169-1176, 1994
26. Hochster H, Oken M, Bennett J, et al: Efficacy of cyclophosphamide and fludarabine as first line therapy of low-grade non-Hodgkin's lymphoma - ECOG 1491. Blood 84:383a, 1994 (suppl 1, abstr)
27. Betticher DC, Fey MF, Von Rohr A, et al: High incidence of infections after 2-chlorodeoxyadenosine (2-CdA) therapy in patients with malignant lymphomas and chronic and acute leukaemias. Ann Oncol 5:57-64, 1994
28. Browne MJ, Hubbard SM, Longo DL, et al: Excess prevalence of Pneumocystis carinii pneumonia in patients treated for lymphoma with combination chemotherapy. Ann Intern Med 104:338-344, 1986
29. Wijermans P, Gerrits W, Haak H: Severe immunodeficiency in patients treated with fludarabine monophosphate. Eur J Haematol 50:292-296, 1993.
30. Keating M, O'Brien S, Kantarjian H, et al: Long-term follow-up of patients with chronic lymphocytic leukemia treated with fludarabine as a single agent. Blood 81:2878-2884, 1993
31. Keating MJ, O'Brien S, Kantarjian H, et al: Nucleoside analogs in treatment of chronic lymphocytic leukemia. Leuk Lymphoma 10:139-145, 1993 (suppl 1)
32. Zinzani P, Lauria F, Rondelli D, et al: Fludarabine: An active agent in the treatment of previously-treated and untreated low grade non-Hodgkin's lymphoma. Ann Oncol 4:575-578, 1993
33. Dumontet C, Bastion Y, Bazin M, et al: Fludarabine therapy in low-grade non-Hodgkin's lymphoma: results of the Lyon-Sud experience. Proceedings of the Fifth International Conference on Malignant Lymphoma, Lugano, Switzerland, 1993, p 97 (abstr)
34. Solal-Celigny P, Brice P, Brousse N, et al: Phase II trial of fludarabine monophosphate as first line treatment in patients with advanced follicular lymphoma. A multicenter study from the "Groupe d'Etude des Lymphomes de L'Adulte." Blood 84:383a, 1994 (suppl 1, abstr)
35. Emanuele S, Saven A, Kosty M, et al: 2-chlorodeoxyadenosine (2-CdA) activity in patients with untreated low-grade lymphoma. Proc Am Soc Clin Oncol 13:306, 1994 (abstr)
36. Diggs CH, Wiernik PH, Ostrow SS: Nodular lymphoma: Prolongation of survival by complete remission. Cancer Clin Trials 4:107-114, 1981
37. Portlock CS: Deferral of initial therapy for advanced indolent lymphomas. Cancer Treat Rep 66:417-419, 1982